Assessing a drug candidate early in discovery and development minimizes the risk of costly downstream failure. This white paper illustrates the application of automated DLS for aggregation and stability investigations.

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe Now!

Screening developability and pre-formulation by HT-DLS

Newsletter